PRESS RELEASE published on 09/01/2025 at 08:40, 1 year ago Informations privilégiées:Autres communiqués TME Pharma finalise une levée de fonds de 500 k € en espèces en août, atteignant une trésorerie de 2,35 M € pour développer de nouvelles thérapies contre le cancer et les maladies oculaires Trésorerie Levée De Fonds Cancer TME Pharma Thérapies
BRIEF published on 08/25/2025 at 08:05, 1 year ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
BRIEF published on 08/25/2025 at 08:05, 1 year ago TME Pharma obtient 500 000 € grâce à une nouvelle émission obligataire Stratégie Financière Stratégie D'investissement Emission D'obligations Réduction Des Coûts Engagements Des Actionnaires
PRESS RELEASE published on 08/25/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
PRESS RELEASE published on 08/25/2025 at 08:00, 1 year ago Informations privilégiées / Autres communiqués TME Pharma lève 500 000 € via une émission obligataire pour accélérer ses activités de développement de thérapies innovantes. Nouveau soutien financier renforce la position de TME Pharma Développement Financement Émission Obligataire TME Pharma Thérapies Innovantes
BRIEF published on 07/08/2025 at 08:05, 1 year 2 months ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
BRIEF published on 07/08/2025 at 08:05, 1 year 2 months ago TME Pharma met fin à son contrat de liquidité dans le cadre d'une optimisation des coûts Contrat De Liquidité Biotechnologie Optimisation Des Coûts Refinancement TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 1 year 2 months ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 1 year 2 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la résiliation du contrat de liquidité avec Invest Securities pour optimiser ses coûts et renforcer sa trésorerie. Réduction des coûts opérationnels suite à la restructuration organisationnelle Contrat De Liquidité Optimisation Des Coûts TME Pharma Restructuration Organisationnelle Développement Thérapies
BRIEF published on 05/21/2025 at 08:05, 1 year 3 months ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
Published on 09/12/2026 at 02:35, 13 hours 50 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 17 hours 25 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 18 hours 20 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 19 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 23 hours 25 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 8 hours 54 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 18 hours 10 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 18 hours 14 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 20 hours 40 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 22 hours 9 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 20 hours ago Availability of the 2026 Interim Financial Report
